India Glycols Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book

Future growth expectations for India Glycols Limited (IGL) in sales/revenue/volumes include: - Potable Spirits segment expects revenue growth to exceed volume growth due to premiumization and new high-margin offerings in deluxe whisky, semi-premium vodka, and white spirits. - IMFL revenue expected to be over 30% of Potable Spirit revenue in FY27. - Doubling of potable spirits volume planned for FY27 with deeper state penetration and new brand launches. - Spirits business targeting EBITDA over INR 500 crores in FY27, aiming for INR 1,000 crores in 4-5 years. - Chemicals business shows 25% YoY revenue growth; pipeline strong in performance chemicals. - ENNature Bio Pharma targeting INR 130-150 crores EBITDA over next 4-5 years with growth in nicotine and nutraceuticals. - Business restructuring to enhance focus and investor clarity, aiding growth. - Debt reduction expected to improve profitability and support expansion. Growth fueled by geographic expansion, premiumization, new brands, and operational efficiencies.

The transcript does not explicitly mention current or expected order book or pending orders details for India Glycols Limited. However, relevant points related to business outlook and growth include: - Ennature Bio Pharma has a strong order pipeline supporting 26% growth in Thiocolchicoside sales. - The Spirits business is targeting healthy double-digit volume growth driven by new offerings and deeper penetration. - The joint venture performance is steady, with increased sales and exports to Clariant customers worldwide. - The company is focusing on customer and product expansion across multiple segments. - No specific quantitative data on order book or pending orders is disclosed in this transcript. For detailed order book or pending orders data, the management has requested investors to reach out via email for personalized responses.